Frank D. Lee - 11 Feb 2026 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: PCRX
Reported as of: 11 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Feb 2026, 16:01:50 UTC
Prior SEC filing: 03 Feb 2026
Next SEC filing: 20 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Kristen Williams, Attorney-in-Fact

Key filing fact

Frank D. Lee filed Form 4 for Pacira BioSciences, Inc. (PCRX) on 13 Feb 2026.

Key facts

This page summarizes Frank D. Lee's Form 4 filing for Pacira BioSciences, Inc. (PCRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Feb 2026, 16:01.

Change

Previous filing in this sequence was filed on 03 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001814686 Primary reporting owner

Lee Frank D.

Relationship: Chief Executive Officer, Director
Address: C/O PACIRA BIOSCIENCES, INC., 2000 SIERRA POINT PARKWAY, SUTE 900, BRISBANE
Signature: /s/ Kristen Williams, Attorney-in-Fact
Signature date: 13 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCRX transaction

Common Stock

Award

Transaction value: $0
Shares: +261,818
Change %: +66%
Price: $0.000000
Shares after: 660,831
Date: 11 Feb 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.